PEG Stock Overview
Through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pharma Equity Group A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.20 |
| 52 Week High | DKK 0.51 |
| 52 Week Low | DKK 0.18 |
| Beta | 0 |
| 11 Month Change | -16.67% |
| 3 Month Change | -31.21% |
| 1 Year Change | -57.47% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -72.67% |
Recent News & Updates
Shareholder Returns
| PEG | DK Real Estate | DK Market | |
|---|---|---|---|
| 7D | -2.4% | -4.0% | -0.9% |
| 1Y | -57.5% | 0.07% | 19.7% |
Return vs Industry: PEG underperformed the Danish Real Estate industry which returned 0.1% over the past year.
Return vs Market: PEG underperformed the Danish Market which returned 19.7% over the past year.
Price Volatility
| PEG volatility | |
|---|---|
| PEG Average Weekly Movement | 7.9% |
| Real Estate Industry Average Movement | 4.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 8.9% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: PEG's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: PEG's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Thomas Selsø | www.pharmaequitygroup.com |
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.
Pharma Equity Group A/S Fundamentals Summary
| PEG fundamental statistics | |
|---|---|
| Market cap | DKK 209.71m |
| Earnings (TTM) | -DKK 30.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.8x
P/E RatioIs PEG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEG income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 0 |
| Gross Profit | DKK 0 |
| Other Expenses | DKK 30.81m |
| Earnings | -DKK 30.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 15, 2024
| Earnings per share (EPS) | -0.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 168.1% |
How did PEG perform over the long term?
See historical performance and comparison